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As we have suggested, epigenetic factors, such as microRNAs (miRNAs), can interact 
with genetic programs to regulate B cell functions, thereby informing antibody and 
autoantibody responses. We have shown that histone deacetylase (HDAC) inhibi-
tors (HDI) inhibit the differentiation events critical to the maturation of the antibody 
response: class-switch DNA recombination (CSR), somatic hypermutation (SHM), and 
plasma cell differentiation, by modulating intrinsic B cell mechanisms. HDI repress 
the expression of AID and Blimp-1, which are critical for CSR/SHM and plasma cell 
differentiation, respectively, in mouse and human B cells by upregulating selected 
miRNAs that silenced AICDA/Aicda and PRDM1/Prdm1 mRNAs, as demonstrated by 
multiple qRT-PCRs (J Immunol 193:5933–5950, 2014). To further define the selectivity 
of HDI-mediated modulation of miRNA and gene expression, we performed genome-
wide miRNA-Seq and mRNA-Seq analysis in B cells stimulated by LPS plus IL-4 and 
treated with HDI or nil. Consistent with what we have shown using qRT-PCR, these 
HDI-treated B cells displayed reduced expression of Aicda and Prdm1, and increased 
expression of miR-155, miR-181b, and miR-361, which target Aicda, and miR-23b, 
miR-30a, and miR-125b, which target Prdm1. In B cells induced to undergo CSR and 
plasma cell differentiation, about 23% of over 22,000 mRNAs analyzed were expressed 
at a significantly high copy number (more than 20 copies/cell). Only 18 (0.36%) of these 
highly expressed mRNAs, including Aicda, Prdm1, and Xbp1, were downregulated by 
HDI by 50% or more. Further, only 16 (0.30%) of the highly expressed mRNAs were 
upregulated (more than twofold) by HDI. The selectivity of HDI-mediated modulation 
of gene expression was emphasized by unchanged expression of the genes that are 
involved in regulation, targeting, or DNA repair processes of CSR, as well as unchanged 
expression of the genes encoding epigenetic regulators and factors that are important 
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inTrODUcTiOn
Epigenetic markers or factors, such as DNA methylation, histone 
posttranslational modifications, and microRNAs (miRNAs), 
dynamically regulate gene activities. As we have contended, 
epigenetic markers/factors “interact” with genetic programs to 
regulate B cell functions, such as class-switch DNA recombina-
tion (CSR), somatic hypermutation (SHM), and differentiation 
to memory B cell or plasma cell, thereby informing antibody and 
autoantibody responses (1). CSR and SHM are B cell-intrinsic 
differentiation processes that underpin the generation of class-
switched and high-affinity antibodies, such as those that clear 
microbial pathogens or kill tumor cells. CSR and SHM critically 
require activation-induced cytidine deaminase (AID, encoded by 
AICDA in humans and Aicda in mice), which is specifically and 
highly induced in B cells in both T-dependent and T-independent 
antibody responses (2). Class-switched and hypermutated B cells 
further differentiate into antibody-secreting plasma cells in a 
fashion critically dependent on B lymphocyte-induced matura-
tion protein 1 (Blimp1, encoded by PRDM1 in human beings 
and Prdm1 in mice) (3), or transition to long-lived memory B 
cells, which can differentiate into plasma cells upon reactivation 
by antigen to mediate an anamnestic response (4). Pathogenic 
autoantibodies, including those to nuclear components in sys-
temic lupus erythematosus (SLE) patients (5, 6), are also class-
switched and hypermutated (7, 8). Thus, epigenetic dysregulation 
of B cells can result in aberrant antibody responses to exogenous 
antigens, such as those on viruses and bacteria, or self-antigens, 
such as chromatin, histones, and dsDNA in lupus (1, 7).
The chromatin structure is comprised of DNA and histones. 
The basic repeating unit of chromatin is the nucleosome, a 147 bp 
of DNA chain wrapped around one histone octamer composed 
of two copies of each of four histones: H2A, H2B, H3, and H4. 
Histone posttranslational modifications include phosphorylation 
of serine or threonine residues, methylation of lysine or arginine, 
acetylation and deacetylation of lysines, and ubiquitylation and 
sumoylation of lysines. All these posttranslational modifications 
play an important role in regulating gene expression (9, 10). 
Histone acetylation and deacetylation, which are essential for 
gene regulation, are typically modulated by histone acetyltrans-
ferase (HAT) and histone deacetylase (HDAC) (9, 10). Histone 
acetylation catalyzed by HAT will result in a loose chromatin 
structure, which enables DNA binding proteins to activate gene 
transcription, while histone deacetylation catalyzed by HDAC 
will result in a condensed chromatin structure, which prevents 
binding of transcription factors or proteins to DNA and silence 
gene expression. HDAC inhibitors (HDI) alter gene expression by 
altering chromatin accessibility (11, 12).
MicroRNAs also play an important role in regulation of the 
genes involved in CSR, SHM, and plasma cell differentiation 
(1, 7, 13). miRNAs are small (~22 nucleotides), evolutionarily 
conserved non-coding RNAs derived from much larger primary 
transcripts encoded by their “host genes.” miRNAs bind to com-
plementary sequences within the 3′ untranslated region (3′ UTR) 
of their target mRNAs and negatively regulate protein expression 
at the posttranscriptional level through inhibition of translation 
and/or reduction of mRNA stability (14, 15). The mammalian 
genome encodes thousands of miRNAs that collectively affect the 
expression of more than half of protein-coding genes. In addition, 
miRNAs have been implicated as fine-tuning regulators control-
ling diverse biological processes at posttranscriptional level. They 
can potentially regulate every aspect of cellular activity, from pro-
liferation and differentiation to apoptosis, as well as modulate a 
large range of physiological and pathological processes. miRNAs 
likely play important roles in B cell development and peripheral 
differentiation, as well as T cell stage-specific differentiation and 
autoimmunity. Some miRNAs, including miR-155, miR-181b, 
and miR-361, can silence AID expression, whereas miR-30a and 
miR-125b can silence Blimp-1 expression (16). These miRNAs 
bind to evolutionarily conserved miRNA target sites in the 3′ 
UTR of Aicda and Prdm1 mRNAs and cause degradation of the 
mRNA transcripts and/or inhibit their translation.
We have recently shown that HDI, such as short-chain fatty 
acid valproic acid and butyrate, inhibit the expression of AID 
and Blimp-1 in human and mouse B cells in  vivo and in  vitro 
and regulate intrinsic B cell functions that are critical in shaping 
effective antibody and autoantibody responses (16). Valproic acid 
or sodium valproate (VPA, 2-propyl-pentanoic acid sodium) is 
widely used to treat epilepsy and mood disorders. VPA can selec-
tively inhibits class I HDACs, particularly, HDAC1 and HDAC2, 
and less effectively, class IIa HDACs among the four HDAC 
classes identified in mammals (17, 18) to alter gene expression 
by changing chromatin accessibility. We have further shown that 
HDI, such as VPA and butyrate, inhibit AID and Blimp1 expres-
sion by upregulating miR-155, miR-181b, and miR-361, which 
silenced AICDA/Aicda mRNA, and miR-23b, miR-30a, and miR-
125b, which silenced PRDM1/Prdm1 mRNA (16). The selectivity 
of HDI-mediated silencing of AICDA/Aicda and PRDM1/Prdm1 
was emphasized by unchanged expression of HoxC4 and Irf4 
(important inducers/modulators of AICDA/Aicda), Rev1 and 
Ung (central elements for CSR/SHM), and Bcl6, Bach2, or Pax5 
(repressors of PRDM1/Prdm1 expression), as well as unchanged 
expression of miR-19a/b, miR-20a, and miR-25, which are not 
known to regulate AICDA/Aicda or PRDM1/Prdm1. Epigenetic 
modulations always display a cell type- and cell stage-specific 
regulation pattern of gene expression (19). To extend our findings 
for cell signaling or apoptosis. Our findings indicate that, in B cells induced to undergo 
CSR and plasma cell differentiation, HDI modulate selected miRNAs and mRNAs, pos-
sibly as a result of HDACs existing in unique contexts of HDAC/cofactor complexes, as 
occurring in B lymphocytes, particularly when in an activated state.
Keywords: aiD, Blimp1, B cell, class-switch Dna recombination, epigenetics, hDac, hDac inhibitor, histone 
acetylation, microrna, mrna, mrna-seq, mirna-seq, plasma cell differentiation, somatic hypermutation
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and further define the selectivity of HDI-mediated modulation 
of miRNAs and gene expression, we performed genome-wide 
miRNA-Seq and mRNA-Seq analysis in B cells induced to 
undergo CSR and plasma cell differentiation in the presence of 
VPA. Here, we showed that this HDI modulated selected miRNAs 
and mRNAs, possibly as a result of HDACs existing in unique 
contexts of HDAC/cofactor.
MaTerials anD MeThODs
stimulation of Mouse B cells for csr and 
Plasma cell Differentiation, and hDi 
Treatment
C57BL/6 mice were purchased from The Jackson Laboratory 
and maintained at the University of Texas Health Science Center 
at San Antonio (UTHSCSA) animal facility. The Institutional 
Animal Care and Use Committee of UTHSCSA approved all ani-
mal protocols. Naïve IgD+ B cells were isolated from 8-week-old 
C57BL/6 mice as described (16, 20). B cells were resuspended in 
RPMI 1640 medium with 10% FBS, 50 mM β-mercaptoethanol, 
and 1× antibiotic–antimycotic mixture (15240-062; Invitrogen) 
(FBS-RPMI) at 37°C and stimulated with LPS (3 μg/ml) from 
Escherichia coli (055:B5; Sigma-Aldrich) plus IL-4 (5  ng/ml; 
R&D Systems) for CSR to IgG1/IgE and plasma cell differentia-
tion. HDI [VPA 500 μM, a concentration comparable to serum 
concentration of VPA-treated mice (21)] or nil were also added to 
the cultures. Cells were collected 60 h later for qRT-PCR, mRNA-
Seq, and miRNA-Seq, or 96 h later for surface Ig analysis by flow 
cytometry (16, 22).
rna extraction and high Throughput 
mrna-seq and mirna-seq
Total RNA was extracted from 2 ×  106 cells using miRNeasy® 
Mini Kit (Qiagen), as previously described (16). RNA integrity 
was verified using an Agilent Bioanalyzer 2100 (Agilent). Next 
generation mRNA-Seq and small RNA-Seq were performed by 
the Genome Sequencing Facility (Greehey Children’s Cancer 
Research Institute, GCCRI), UTHSCSA. High-quality RNA 
(RNA Integrity number or RIN.9.0) was processed using an 
Illumina TruSeq RNA sample prep kit v2 or TruSeq Small 
RNA Sample Prep kit following the manufacturer’s instructions 
(Illumina). Clusters were generated using TruSeq Single-Read 
Cluster Gen. Kit v3-cBot-HS on an Illumina cBot Cluster 
Generation Station. After quality control procedures, individual 
mRNA-Seq or small RNA-Seq libraries were then pooled based 
on their respective 6-bp index portion of the TruSeq adapters and 
sequenced at 50 bp/sequence, read using an Illumina HiSeq 2000 
sequencer. The barcode combinations were further crosschecked 
by Illumina Experiment Manager software. Sequence data were 
checked by assurance (QA) pipeline and initial genome align-
ment (Alignment). Approximately 33 million and 5 million 
reads per sample were generated in mRNA-Seq and miRNA-Seq, 
respectively. After the sequencing run, demultiplexing with 
CASAVA was employed to generate the fastq file for each sample. 
All sequencing reads were aligned with their reference genome 
(UCSC mouse genome build mm9) using TopHat2 default settings 
and the Bam files from alignment were processed using HTSeq-
count to obtain the counts per gene in all samples. Quality control 
statistical analysis of outliers, intergroup variability, distribution 
levels, PCA, and hierarchical clustering analysis were performed 
for statistical validation of the experimental data.
Quantitative rT-Pcr (qrT-Pcr) of mrnas 
and mirnas
For mRNA quantification, post-recombination Iμ-CH and mature 
VHDJH-CH transcripts. cDNA was synthesized from total RNA with 
the SuperScript™ III First-Strand Synthesis System (Invitrogen) 
using oligo-dT primer. Transcript expression was measured by 
qRT-PCR using the appropriate primers, as previously reported 
(16) using a Bio-Rad MyiQ™ Real-Time PCR Detection System 
(Bio-Rad Laboratories) to measure SYBR Green (IQ™ SYBR® 
Green Supermix, Bio-Rad Laboratories) incorporation with the 
following protocol: 95°C for 15 s, 40 cycles of 94°C for 10 s, 60°C 
for 30 s, 72°C for 30 s. Data acquisition was performed during the 
72°C extension step. Melting curve analysis was performed from 
72 to 95°C. For quantification of mature miRNA transcripts, RNA 
was extracted from 0.2–5 × 106 cells using miRNeasy® Mini Kit 
(Qiagen) and then reverse-transcribed with miScript II RT Kit 
(Qiagen) using the miScript HiSpec buffer. A Bio-Rad MyiQ™ 
Real-Time PCR Detection System was used to measure SYBR 
Green (miScript SYBR Green PCR Kit; Qiagen) incorporation 
according to manufacturer’s instructions. Mature miRNA forward 
primers were used at 250  nM in conjunction with the Qiagen 
miScript Universal Primer and normalized to expression of small 
nuclear/nucleolar RNAs Rnu6/RNU61/2, Snord61/SNORD61, 
Snord68/SNORD68, and Snord70/SNORD70. The ΔΔCt method 
was used for qRT-PCR data analysis with Microsoft Excel.
statistical analysis
Statistical analysis was performed to determine p values by paired 
and unpaired Student’s t-test, and p values <0.05 were considered 
significant.
resUlTs
hDi inhibit csr and Plasma cell 
Differentiation
We have shown that HDI repress the expression of AID and 
Blimp-1, which are critical for CSR/SHM and plasma cell differen-
tiation, respectively, in mouse and human B cells by upregulating 
selected miRNAs that silenced AICDA/Aicda and PRDM1/Prdm1 
mRNAs, as demonstrated by multiple qRT-PCRs (16). To further 
define the selectivity of HDI-mediated modulation of miRNA 
and gene expression, we stimulated purified mouse B cells with 
LPS plus IL-4, which induce B cells to undergo CSR to IgG1 
or IgE and differentiate to plasma cells in the presence of HDI 
(VPA, 500 μM) or nil. Consistent with our previous findings (16), 
HDI significantly inhibited CSR and plasma cell differentiation, 
as shown by greatly reduced surface IgG1+ B cells and B220low 
CD138+ plasma cells (Figure  1). HDI inhibition of CSR was 
FigUre 1 | hDi inhibits B cell csr and plasma cell differentiation. Purified spleen B cells were stimulated with LPS plus IL-4 in the presence of HDI (VPA, 
500 μM) or nil. (a) Surface expression of B220 and IgG1 was measured by flow cytometry 96 h after the stimulation, Data are one representative of three 
independent experiments. (B) The average percentage of IgG1+ B cells and B220low CD138+ plasma cell in nil or HDI-treated cells in the three experiments. (c) 
Mature VHDJH-Cγ1 transcripts and post-recombination Iμ-Cγ1 transcripts, both hallmarks of completed CSR, were analyzed by qRT-PCR and normalized to Cd79b 
transcripts in B cells stimulated for 60 hours, measured by qRT-PCR and normalized to Cd79b transcripts. Data are from three independent experiments. p values, 
paired t-test.
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further confirmed by decreased numbers of post-recombination 
Iμ-Cγ1 and mature VHDJH-Cγ1 transcripts.
hDi-Mediated Modulation of mrna 
expression in B cells is highly selective
Histone deacetylases remove the acetyl groups from the histone 
lysine residues leading to the formation of a condensed and 
transcriptionally silenced chromatin. HDI block this activity, 
thereby increasing histone acetylation and alteration of gene 
expression. It has been shown that HDI, such as TSA, suberoy-
lanilide hydroxamic acid (SAHA), MS-275, and FK228, could 
alter the expression of 5–20% of genes (23). To further define the 
modulation of gene expression by HDI in B cells that undergo 
CSR and plasma cell differentiation, we performed high through-
put mRNA-Seq to analyze the transcriptome in B cells stimulated 
by LPS plus IL-4 and treated with HDI (VPA, 500 μM) or nil. In 
general, one RPKM (read per kb per million reads) of mRNA 
represents approximately one copy of transcript per cell (24). In 
three independent experiments, HDI did not significantly alter 
overall mRNA expression (p =  0.99925, 0.74835, and 0.39640, 
respectively), although the average PRKM was slightly reduced 
from 42.71 to 38.49 (p = 0.3506) (Figure 2). Among over 22,000 
genes analyzed, about 5,000 of them were significantly expressed 
(more than 20 RPKM, average more than 20 transcripts per cells) 
in B cells stimulated by LPS plus IL-4. Upon treatment with HDI, 
only 18 (0.36%) of the “highly” expressed genes, including Aicda, 
Prdm1, Xbp1, Bhlha15, RRhob, Soat2, Hist1h2bg, Fut1, Cxcr3, 
Eaf2, Fkbp11, Ppapdc1b, Il10, Rcbtb2, Ly6c2, Saa3, Txndc5, and 
IgJ, were downregulated, on average, by 50% or more. The mRNA 
of Cxcr3 (C-X-C motif chemokine receptor 3), which is highly 
expressed in IgG1+ memory B cells and can promote the produc-
tion of IgG1 autoantibodies (25, 26), was reduced by about 70% by 
HDI. The mRNA of Saa3 (Serum amyloid A3), which can interact 
with Tlr4 and induce Tlr4-mediated NF-κB activation (27), was 
reduced by over 51%. Sixteen (0.30%) of the “highly” expressed 
(more than 20 RPKM) genes, including Gstk1, Gstm1, Zbtb20, 
Gapt, Ift57, Slc16a3, Ptprs, Atp11a, Kctd17, Itm2a, Syt11, and Ifit1, 
were upregulated by HDI by more than twofold (Figures 2A,B). 
Downregulation or upregulation of the above genes by more than 
twofold was consistent in all the three experiments, suggesting 
that the modulation of gene expression by HDI is highly selective.
Aicda, Prdm1, and Xbp1 are selectively 
silenced by hDi
Consistent with our real-time qRT-PCR results (16), the mRNA-
Seq experiments further demonstrated that Aicda, Prdm1, and 
Xbp1 transcripts were significantly downregulated by HDI 
(Figures  2 and 3A–C). In all three independent experiments, 
Aicda, Prdm1, and Xbp1 were consistently reduced by HDI 
by more than 57, 48, and 47%, respectively, ranking 7th, 21st, 
and 24th, of the most downregulated genes among the total of 
more than 5,000 genes that were highly expressed (more than 20 
RPKM) in B cells stimulated by LPS plus IL-4. Thus, these deep 
sequencing experiments showed that Aicda, Prdm1, and Xbp1 
are selectively inhibited by HDI in B cells undergoing CSR and 
plasma cell differentiation.
FigUre 2 | hDi selectively inhibits mrna expression in B cells induced to undergo csr and plasma cell differentiation. B cells were cultured with LPS 
plus IL-4 in the presence of HDI (VPA, 500 μM) or nil for 60 h before preparation of RNA for mRNA-Seq. (a) Scatter plots of average mRNA expression levels in 
three independent experiments (reads per kilobase per million mapped reads, RPKMs), in LPS plus IL-4-stimulated B cells treated with VPA versus those in LPS 
plus IL-4-stimulated B cells treated with nil. Each plot corresponds to one individual mRNA expression level. (B) Bar graphs depict the average folds of changes of 
mRNA expression levels (average RPKMs from three independent experiments) in LPS plus IL-4-stimulated B cells treated with HDI, as compared to those in B cells 
treated with nil. Only the mRNAs at average RPKM >20 in LPS plus IL-4-stimulated B cells treated with nil are included. Aicda, Prdm1, and Xbp1 mRNAs and the 
mRNAs that were increase or decreased or increased in average by more than twofold are indicated. p values, paired t-test.
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hDi Does not alter the expression of 
14-3-3 adaptors or rab7
The 14-3-3 adaptor family consists of a class of phosphoserine/
phosphothreonine (pSer/Thr)-binding proteins, which include 
seven isoforms (14-3-3β, 14-3-3ε, 14-3-3γ, 14-3-3η, 14-3-3σ, 
14-3-3τ, and 14-3-3ζ) encoded by different genes. 14-3-3 proteins 
are involved in a variety of cellular processes, including gene 
regulation, differentiation, and cell cycle progression (28). As we 
have shown, 14-3-3 adaptors play an important role in targeting 
the CSR machinery to S regions by virtue of their ability to bridge 
proteins with DNA or other proteins (29, 30). They directly interact 
with AID, protein kinase A catalytic subunit-α (PKA-Cα), regula-
tory inhibitory subunit-α (PKA-RIα), and uracil DNA glycosylase 
(Ung) to function as scaffolds to stabilize these enzymatic CSR 
elements on S regions. 14-3-3 expression has been suggested to be 
regulated by posttranscriptional modulation. 14-3-3 can interact 
with the phosphorylation sites of HDAC4, 5, and 7 and regulate 
cellular localization of these HDACs (31). As we have shown, the 
expression of most 14-3-3 proteins is significantly upregulated 
by the induction of CSR in B cells (2, 29, 30, 32). To determine 
whether potential alterations of 14-3-3 proteins in B cells could 
contribute to the HDI-mediated inhibition of CSR, we analyzed 
our mRNA-Seq data on the seven 14-3-3 isoforms. None of the 
seven 14-3-3 isoforms were significantly altered by HDI in B cells 
stimulated by LPS plus IL-4 (Figure 3D). 14-3-3ζ expression can 
be modulated by miR-193b and miR-375, which target 3′ UTR 
of 14-3-3ζ mRNA, in cancer cells (33, 34). However, these two 
miRNAs were not expressed in LPS plus IL-4-stimulated B cells 
(not shown).
We have recently demonstrated that Rab7, a small GTPase, 
plays an important role in CSR, through activation of the canoni-
cal NF-κB pathway and induction of AID expression (35). Like 
14-3-3 adaptors, Rab7 expression is upregulated by the stimuli 
that induce CSR in B cells. To analyze whether the HDI-mediated 
downregulation of AID was at least partially due to a potential 
alteration of Rab7 expression, we analyzed Rab7 mRNA levels 
in B cells treated with HDI or nil. As shown by mRNA-Seq, HDI 
did not significantly alter Rab7 expression (Figure 3E). In one 
of the three experiments, Rab7 mRNA levels were virtually the 
same in B cells treated with HDI or nil. In the other two experi-
ments, Rab7 mRNA was even slightly (p =  0.20) increased by 
HDI. Thus, downregulation of the AID-targeting 14-3-3 adaptors 
or downregulation of the CSR-regulating Rab7 small GTPase play 
no role in HDI-mediated modulation of CSR.
FigUre 3 | hDi inhibits the expression of Aicda, Prdm1, and Xbp1, but not other elements that are important for csr/shM and plasma cell 
differentiation. B cells were stimulated with LPS plus IL-4 for 60 h, in the presence of HDI (VPA, 500 μM) or nil. (a) Expressions of Aicda, Prdm1, and Xbp1 were 
mRNAs analyzed by mRNA-Seq. Data are from three independent experiments. (B) qRT-PCR validation of Aicda, Prdm1, and Xbp1 expressions. Data are from 
three independent experiments. p values, paired t-test. Expressions of (c) Bach2, Pax5, Foxo1, Irf4, Pten, and Bcl6, (D) the seven 14-3-3 isoforms, (e) Rab7, and 
(F) the genes that encode the proteins that have been shown to play important roles in CSR and/or SHM were analyzed by mRNA-Seq and depicted as RPKM. 
Data are from three independent experiments. ns, not significant, paired t-test.
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hDi Does not alter the expression of Dna 
repair Factors that are important for csr 
and shM
Class-switch DNA recombination and SHM are tightly regulated 
and both are effected by a two-step process: (i) DNA lesions initi-
ated by AID and (ii) lesion repair by the combined intervention 
of DNA replication and repair factors (2, 36, 37). Many DNA 
repair factors, including the base excision repair factor Ung, 
mismatch repair factors Msh2, Msh3, Msh6, Pms2, and Exo1 
nuclease, translesion synthesis (TLS) DNA polymerases Rev3, 
Rev1, Polθ, and Polη, as well as DSB repair factors Ku70/Ku80, 
Rad52, RPA, and DNA-PK play important roles in CSR and/or 
SHM (2, 37–41). Dysregulation of these DNA repair factors can 
result in altered CSR/SHM, and thereby the antibody response. 
To define whether the HDI-mediated reduction of CSR and 
plasma cell differentiation was associated with any alteration in 
these factors, we analyzed the mRNA-Seq data for the expression 
of these factors. None of them was significantly altered by HDI 
(Figure 3F).
hDi Does not significantly alter the 
expression of epigenetic regulators haTs, 
hDacs and Tet Proteins
In addition to inhibiting catalytic activity of HDACs, HDI have 
been suggested to selectively change the expression of some 
epigenetic regulators in certain type of cells. SAHA, a pan HDAC 
inhibitor, has been shown to downregulate HDAC7 expression in 
fibroblast cell lines (42). MS-275, TSA, and VPA downregulate 
FigUre 4 | hDi does not alter the expression of the epigenetic regulators hDacs, haTs, DnMTs, and Tet proteins. B cells were stimulated with LPS plus 
IL-4 for 60 h, in the presence of HDI (VPA, 500 μM) or nil. mRNA expressions of the genes that encode (a) HDACs and (B) HATs, which modulate histone 
acetylation, and (c) DNMTs, as well as (D) Tet1, Tet2, and Tet3, which modulate DNA methylation, were analyzed by mRNA-Seq and depicted as RPKM. Data are 
from three independent experiments. *p < 0.05; ns, not significant, paired t-test.
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DNMT1 protein expression in testis and embryonal carcinoma, 
as butyrate, SAHA, and PD98059 do in LNCaP prostate cancer 
cells (43). To determine whether HDI alter the expression 
of HDACs or DNMTs, as well as HATs and Tet1/Tet2/Tet3, 
which also mediate histone acetylation and DNA methylation, 
respectively, we analyzed the mRNA levels of these genes in 
our mRNA-Seq data (Figure  4). Thirty-six out of the 42 gene 
transcripts analyzed were not significantly altered by HDI, while 
HDAC1, HDAC6, Clock, and Tet2 were marginally increased 
(by 24.63, 36.64, 9.57, and 23.19%, respectively), and Sirt1 and 
Crebbp were slightly reduced (by 16.54 and 10.11%, respectively) 
by HDI. Thus, epigenetic regulator genes are not significantly 
modulated by HDI in B cells undergoing CSR and plasma cell 
differentiation.
hDi Does not alter the genes that are 
important in cell apoptosis
We have recently found that HDI inhibit, in a dose-dependent 
fashion, CSR and plasma cell differentiation without altering B 
cell proliferation or B cell and plasma cell viability (16). We have 
shown by qRT-PCR that the expression of the anti-apoptotic 
genes Bcl2, Mcl1, and Bcl2l1, which enhance B cell and plasma cell 
survival, was unaltered or increased by HDI in vivo and in vitro 
(16). Consistent with these findings, our mRNA-Seq data show 
that the expressions of all these genes were not altered by HDI 
(p = 0.28, 0.21, or 0.27) (Figure 5A). In addition, other 19 anti-
apoptotic genes and 22 pro-apoptotic genes were also unchanged 
by HDI (Figures 5A,B). Thus, these findings further demonstrate 
that HDI significantly reduce CSR and plasma cell differentiation, 
without altering cell viability.
hDi Does not significantly alter Tlr 
expression and the genes involved in 
nF-κB signaling
Toll-like receptors (TLRs) are a family of conserved pattern rec-
ognition receptors that sense diverse types of microbe-associated 
molecular patterns (MAMPs). Engagement of B cell TLRs by 
MAMPs not only induces T-independent antibody responses but 
also plays an important role in the early stages of T-dependent anti-
body responses, before specific T cell help becomes available (44). 
We have shown that TLR1/2-, TLR4-, TLR7-, or TLR9-signaling 
synergizes with BCR-signaling, which enhances TLR-dependent 
activation of the canonical NF-κB pathway, to induce AID and 
enable CSR (20). Given the important role of TLR-signaling and 
NF-κB pathway in the induction of AID, an alteration in the 
expression of TLR and the factors that are involved in NF-κB 
pathway would result in a change of AID expression and CSR. 
As shown by mRNA-Seq, the expression of 13 TLRs and 27 genes 
that are involved in NF-κB-signaling pathway was not altered by 
HDI (Figures 5C,D).
FigUre 5 | hDi does not significantly alter the expression of the genes that are important for apoptosis, the genes that encode Tlrs and the genes 
that are involved in nF-κB signaling. B cells were stimulated with LPS plus IL-4 for 60 h, in the presence of HDI (VPA, 500 μM) or nil. mRNA expressions of the 
genes that encode (a) anti-apoptotic factors, (B) pro-apoptotic factors, (c) Toll-like receptors, and (D) the factors that are involved in NF-κB-signaling pathway were 
analyzed by mRNA-Seq and depicted as RPKM. Data are from three independent experiments. *p < 0.05; ns, not significant, paired t-test.
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hDi inhibits expression of selected 
mrnas in B cells
In B cells induced to undergo CSR and plasma cell differentiation, 
the number of genes that were downregulated by HDI nearly 
equated that of genes that were upregulated by HDI (Figure 2), 
suggesting that HDI can modulate gene expression by a mecha-
nism other than directly increasing histone acetylation. Indeed, 
generally, only a small number of genes are thought to be directly 
modulated by changes in histone acetylation. Thus, it is possible 
that HDI upregulate the expression of genes, which negatively 
regulate the expression of other genes. HDI can modulate the 
expression of miRNAs, which silence target mRNAs by induc-
ing their degradation and/or reducing their translation. We 
have recently shown that HDI downregulated the expression 
of AID and Blimp-1 by upregulating miR-155, miR-181b, and 
miR-361, which silence Aicda mRNA, and miR-23b, miR-30a, 
and miR-125b, which silence Prdm1 mRNA, but not miR-19a/b, 
miR-20a, and miR-25, which are not known to regulate Aicda, 
Prdm1, or Xbp1 (16). To further define the modulation of miRNA 
by HDI, we analyzed microRNAome in LPS and IL-4 stimulated B 
cells treated with HDI or nil by miRNA-Seq (Figure 6). In stimu-
lated B cells, the average RPM of 520 miRNAs analyzed was 26.9 
(10.75, if one excludes the three most abundant miRNAs miR-
21a, miR-191, and miR-146a). Upon HDI treatment, the average 
RPM of all the miRNAs were slightly increased to 32.19 (13.63, if 
we exclude the three most abundant miRNAs miR-21a, miR-191, 
and miR-146a) (R2 = 0.9811, p = 0.5134). A total of 185 of these 
miRNAs had, in average, 0.5 copy per cell. Among these 185 
miRNAs, only 6 of them were reduced by 50% or more, and 26 of 
them were upregulated by more than twofold by HDI (Figure 6). 
Thus, the HDI-mediated modulation of miRNA expression in B 
cells undergoing CSR and plasma cell differentiation is selective.
FigUre 6 | hDi selectively inhibits mirna expression in B cells induced to undergo csr and plasma cell differentiation. B cells were cultured with LPS 
plus IL-4 in the presence of HDI (VPA, 500 μM) or nil for 60 h before preparation of RNA for miRNA-Seq. (a) Scatter plots of average (in three independent 
experiments) miRNA expression levels (RPMs) in B cells treated with HDI versus that in B cells treated with nil. P values, paired t-test. (B) Bar graphs depict the 
changes of folds of the average miRNA expression levels (RPMs) in B cells treated with HDI as compared to that in B cells treated with nil. (c) Bar graphs depict the 
changes of folds of miRNA expression levels (RPMs) in B cells treated with HDI as compared to that in B cells treated with nil, in three independent experiments. (D) 
Scatter plots of miRNA expression levels in B cells treated with HDI versus those in B cells treated with nil, in three independent experiments. Only the miRNAs at 
average RPM > 0.5 in LPS plus IL-4-stimulated B cells treated with nil are included.
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hDi Upregulates selected mirnas that 
Target Aicda
We have shown by qRT-PCR that miR-155, miR-181b, and 
miR-361, which silence AID by targeting Aicda 3′ UTR, were 
significantly upregulated by HDI (16). The HDI-mediated 
upregulation of these miRNAs, particularly, miR-155 was 
validated by miRNA-Seq in three independent experiments 
(Figure 7). miR-155 targets a highly conserved site in the 3′ UTR 
of Aicda mRNA in several different species (45, 46). As shown 
by miRNA-Seq analysis, miR-155 is one of the most abundant 
miRNAs expressed in B cells after stimulation by LPS plus IL-4 
(Figure  6). In such B cells, the average RPM of miR-155 was 
684.9 (572.0, 981.7, and 501.0 in three independent experiments, 
respectively), which is more than 25 times higher than the 
average RPM of all the 520 miRNAs analyzed. Upon treatment 
with HDI, miR-155 expression was increased by more than 1.9-
fold (p = 0.032) (Figure 7). miR-155 is encoded by the miR155 
host gene miR155HG. miR155HG was originally identified as a 
gene that was transcriptionally activated by promoter insertion 
at a common retroviral integration site in B cell lymphomas 
and was formerly referred to as Bic (B cell integration cluster) 
(13). Consistent with our qRT-PCR results (16), the mRNA-Seq 
data showed that HDI-mediated upregulation of miR-155 was 
associated with an increase of primary miR-155HG transcript 
(Figure 7C). In addition to the targeting sites for miR-155, miR-
181b, and miR-361, the 3′ UTR of mouse Aicda mRNA also con-
tains the putative target sites for miR-125a, miR-351, miR-92b, 
miR-26a, and miR-103 (identified by using miRNA-targeting 
FigUre 7 | hDi upregulates the mirnas that target Aicda. (a) Alignment of the miRNAs and their target sites in the 3′ UTR of Aicda mRNAs. (B) Expression of 
miRNAs that modulate AID or are predicated to modulate AID in B cells cultured with LPS plus IL-4 in the presence of HDI (VPA, 500 μM) or nil for 60 h were 
analyzed by miRNA-Seq and depicted as RPM. (c) Primary (pri-) miRNA transcripts of miR-155 in B cells cultured for 60 h with LPS plus IL-4 in the presence of nil 
or HDI were analyzed by mRNA-Seq and depicted as RPKM. Data are from three independent experiments. p values, paired t-test.
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prediction tools: TargetScan.org, miRNA.org, and miRbase.
org). These miRNAs were also upregulated by HDI. Thus, HDI 
upregulate miRNAs that silence Aicda and do so by increasing 
the primary transcripts of host genes of these miRNAs.
hDi Upregulate mirnas that Target Prdm1
We have shown that HDI significantly downregulated Prdm1 
expression, plasma cell differentiation, and antibody/autoanti-
body production (16). The greatly reduced plasma cell differen-
tiation was associated with downregulation of the Ig J chain (IgJ) 
gene, which is expressed only after B cells terminal differentiation 
into plasma cells (47). IgJ is incorporated into an IgM pentamer 
or an IgA dimer and is necessary for both the cellular and mucosal 
secretion of antibodies. In B cells stimulated by LPS plus IL-4 for 
60 h, the average RPKM of IgJ mRNA was 344.6 (395.1, 175.6, 
and 463.2 in three independent experiments, respectively). HDI 
reduced IgJ expression (RPKM) by more than 3.3-fold to average 
103.6 (77.3, 46.2, and 187.3, in three independent experiments, 
respectively) (Figure 2). Both human PRDM1 and mouse Prdm1 
mRNA have a long (2,453 bp) 3′ UTR, including putative miRNA-
targeting sites, which are evolutionary conserved. By using 
miRNA-targeting prediction tools (TargetScan.org, miRNA.org, 
and miRbase.org), we identified miR-125a, miR-125b, miR-96, 
miR-351, miR-30, miR-182, miR-23a, miR-23b, miR-200b, miR-
200c, miR-33a, miR-365, let-7, miR-98, miR-24, miR-9, miR-223, 
and miR-133 as PRDM1/Prdm1 targeting miRNAs in both the 
human and the mouse. With exception of miR-33a, miR223, 
miR-9, miR-24, and miR-429, whose expression level was low in 
activated B cells, such Prdm1-targeting miRNAs were significantly 
upregulated by HDI. We have shown by qRT-PCR that miR-23b, 
miR-30a, and miR-125b, which silence Blimp-1 by targeting 
Prdm1 3′ UTR, were significantly upregulated by HDI (16). The 
upregulation of these miRNAs was further validated in B cells by 
miRNA-Seq in three independent experiments (Figure 8). This 
likely resulted from increased primary miRNA transcripts, as 
suggested by the upregulation of pri-miR-23b.
The miR-30 family consists of five miRNAs (miR-30a, miR-
30b, miR-30c, miR-30d, and miR-30e) encoded by different host 
genes. The miR-30 family members are similar to each other and 
have identical seed sequences. Like human PRDM1 (48), the 3′ 
UTR of mouse Prdm1 mRNA contains three highly conserved 
bindings sites complementary to the seed sequence of miR-30a 
FigUre 8 | The Prdm1 targeting mirnas mir-23b, mir-125a, mir-351, mir-30a/c/d, mir-182, mir-96, mir-98, mir-200b/c, and mir-365 are 
upregulated by hDi. (a) Alignment of the 3′ UTR of Prdm1 mRNA and the targeting miRNAs. (B) Expressions of the miRNAs miR-23b, miR-125a, miR-351, 
miR-30a/c/d, miR-182, miR-96, miR-98, miR-200b/c, and miR-365 that target or are predicted to target Prdm1 3′ UTR, as well as miR-183, which is expressed in 
a same cluster with miR-182, in B cells cultured with LPS plus IL-4 in the presence of HDI (VPA, 500 μM) or nil for 60 h were analyzed by miRNA-Seq and depicted 
as RPM. (c) Primary (pri-) miRNA transcripts of miR-23b in B cells cultured with LPS plus IL-4 in the presence of nil or HDI for 60 h were analyzed by mRNA-Seq 
and depicted as RPKM. Data are from three independent experiments. p values, paired t-test.
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and other miR-30 family members (Figure 8). All the five miR-30 
miRNAs were expressed in B cells stimulated by LPS plus IL-4. 
The abundance of miR-30b, miR-30c, miR-30d, and miR-30e 
were greater than that of miR-30a (Figure  8). miR-30c was 
upregulated by HDI in all the three experiments, miR-30d was 
upregulated in two of the three experiments, while miR-30b and 
miR-30e were upregulated in one of the three experiments but 
were downregulated in the other two experiments.
miR-125 is a an evolutionarily conserved miRNA family 
consisting of three paralogs, including miR-125a, miR-125b-1, 
and miR-125b-2 (miR-125b). Recent studies have presented 
strong evidence for a role of the miR-125 family in the immune 
response. miR-125a shares the same seed sequence with miR-
125b. Like miR-125b, miR-125a also potentially targets Prdm1 
in both human being and mouse, as predicted by the sequences 
(Figure  8). The abundance of miR-125a in B cells induced to 
undergo CSR and plasma cell differentiation by LPS plus IL-4 was 
much greater than that of miR-125b, as in all three experiments. 
In the presence of HDI, miR-125a expression was increased by 
up to 7.5-fold, perhaps suggesting a more important role of this 
miRNA than miR-125b in modulating Blimp1 expression. miR-
125a and miR-351 contain the same seed sequence as miR-125b, 
and therefore potentially target Prdm1 3′ UTR at the same site 
as miR-125b. Likewise, HDI upregulated miR-351 expression by 
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up to 16.5-fold. miR-98 potentially target the same site as let-7 in 
Prdm1 3′ UTR. While let-7 miRNAs were not consistently altered 
by HDI, miR-98 was significantly upregulated by HDI in B cells 
in all the three experiments of CSR/plasma cell differentiation 
induction (p = 0.02).
miR-182, miR-96, and miR-183 belong to a polycistronic 
miRNA cluster that is located within a 4-kb area on mouse chro-
mosome 6q. These miRNA siblings share similar seed sequences; 
in fact, the seed sequences of miR-96 and miR-182 are identical. 
As predicted using online miRNA analyze tools, TargetScan.org, 
miRNA.org, and miRbase.org, in both mouse and human, miR-
182 and miR-96 can potentially target Prdm1/PRDM1 3′ UTR 
at the same site (Figure 8). In B cells stimulated with LPS plus 
IL-4, miR-182, miR-96, and miR-183 were all highly expressed. 
All these three miRNAs were upregulated by HDI. Because the 
precursors of miR-96, miR-182, and miR-183 are transcribed as 
a single transcript, these findings further support the contention 
that HDI modulate miRNA expression through regulation of 
their primary transcript (16). Thus, these experiments showed 
that HDI upregulate the miRNAs that target Prdm1, possibly by 
increasing the primary transcripts of host genes of these miRNAs.
DiscUssiOn
Epigenetic marks/factors, such as histone posttranslational mod-
ifications, DNA methylation, and non-coding RNAs, including 
miRNAs, play important roles in the complex interplay between 
genes and environment. As we have suggested, they “interact” 
with genetic programs to regulate B cell functions, including 
CSR, SHM, and plasma cell differentiation, thereby informing 
the antibody response (1, 2, 7, 49). Epigenetic dysregulation can 
result in aberrant antibody responses and compound genetic 
susceptibility to mediate autoimmunity (7, 49). We have recently 
shown that HDI epigenetic modulators inhibited CSR, SHM, 
and plasma cell differentiation by modulating intrinsic B cell 
mechanisms (16). HDI repressed AID and Blimp-1 expression in 
human and mouse B cells by upregulating selected miRNAs that 
silenced AICDA/Aicda and PRDM1/Prdm1 mRNAs, as demon-
strated by multiple qRT-PCRs. In this study, we performed high 
throughput miRNA-Seq and mRNA-Seq to further define the 
HDI-mediated modulation of miRNA and gene expression. We 
showed here that HDI selectively upregulated miRNAs involved 
in targeting and modulating genes whose expressions are criti-
cal for B cells to undergo CSR and plasma cell differentiation. 
The selective upregulation of miRNAs and mRNAs by HDI was 
emphasized by unchanged expression of miRNAs, which are not 
known to regulate Aicda or Prdm1, the master genes for CSR/
SHM or plasma cell differentiation, and unchanged expression 
of the genes that are involved in regulation, targeting, or DNA 
repair processes in CSR/SHM, as well as the genes of epigenetic 
regulators and the factors that are important for cell signaling 
and apoptosis. Consistent with the notion that HDI downregu-
late mRNA expression by upregulating selective miRNAs, HDI 
slightly reduced average RPKM of overall mRNA, in association 
with a slightly increased overall miRNA expression. This study 
further extends our previous findings and outlines more 
precisely epigenetic mechanisms that are critical to the B cell dif-
ferentiation processes that underpin antibody and autoantibody 
responses.
In spite of the broad distribution of HDACs in chromatin, our 
findings showed that HDI-mediated modulation of miRNA and 
mRNA expression is very selective. Upon exposure to HDI, 18 
genes were upregulated by more than twofold in B cells induced 
to undergo CSR and plasma cells differentiation. These genes, 
included Zbtb20 (Zinc finger and BTB domain-containing pro-
tein 20), a Bcl6 homolog, which is highly expressed in activated 
B cells and memory B cells and has been shown to regulate 
long-term antibody production through a B cell-intrinsic 
mechanism (50, 51), and Syt11 (synaptotagmin-11), which is 
specifically expressed in memory B cells (52), suggesting that 
HDI can modulate the memory B cell response. Sixteen genes 
were downregulated by HDI by more than 50%. More than half 
of these downregulated genes, including Bhlha15, Rhob, Fkbp11, 
Ppapdc1b, Rcbtb2, Ly6c2, Txndc5, and IgJ, are preferentially 
expressed in plasma cells rather than naïve, germinal center, 
or memory B cell (52) (http://www.ncbi.nlm.nih.gov/sites/
GDSbrowser?acc=GDS1695). This may imply that, in addition 
to the inhibition of AID and Blimp-1 expression, alteration of the 
expression of other genes that are involved in B cell differentiation 
could also contribute to HDI-mediated modulation of the anti-
body response. Alternatively, the reduction of these “plasma cell 
specific” genes may simply result from the inhibition of plasma 
cells differentiation by HDI, further supporting the selectivity of 
HDI-mediated modulation of mRNA expression. HDI modu-
lated CSR, SHM, and plasma cells differentiation, and, therefore, 
the antibody response mainly through downregulation of Aicda, 
Prdm1, and Xbp1. However, the HDI-mediated downregulation 
of Cxcr1, which is preferentially expressed in IgG1+ memory B 
cells and promotes IgG1 autoantibody production (25, 26), and 
Saa3, which can interact with Tlr4 and induce Tlr4-mediated 
NF-κB activation (27), suggest that downregulation of these ele-
ments can contribute to HDI-mediated modulation of antibody 
response. The reduction of Cxcr3, Fut1, and Rhobtb1 expres-
sion was associated with an increased expression of miR-148b, 
miR-125a, and miR-182, which target Cxcr3, Fut1, and Rhobtb1 
mRNAs, respectively, suggesting that, in addition to Aicda and 
Prdm1, which are already downregulated by HDI, other genes 
can also be downregulated by HDI through upregulation of their 
targeting miRNAs. This does not, however, exclude the possibil-
ity that the HDI-mediated reduction of gene expression may 
at least partially result from altered expression or activation of 
other B cell factors.
A total of 18 HDACs, which are not functionally redundant, 
have been identified in human beings and mice (12). These 18 
HDACs are grouped into four classes based on their function and 
sequence similarity (12). Classes I, II, and IV consist of 11 HDACs 
that require zinc as a cofactor. Class I includes HDAC1, HDAC2, 
HDAC3, and HDAC8, which display homology to yeast RPD3; 
Class IIa includes HDAC4, HDAC5, HDAC7, and HDAC9, 
which display homology to yeast HDA1; Class IIb includes 
HDAC6 and HDAC10, which contain two catalytic sites. Class 
IV includes only HDAC11, which displays conserved residues in 
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its catalytic center, shared by both class I and class II HDACs. 
Class III HDACs or Sirtuins (Sirt1-7) display homology to yeast 
Sir2, retain NAD-dependent catalytic sites and share some func-
tions with the classical HDACs. Unlike the classes I, II, and IV 
HDACs, Sirtuins are not zinc dependent and cannot be inhibited 
by conventional HDI, such as VPA and butyrate. They may func-
tion differently from class I/II HDACs in the regulation of the 
antibody response. Indeed, activation of Sirt1 by resveratrol has 
been shown to lead to a reduced production of IgG1 and IgG2a in 
pristane-induced lupus mice (53) as well as antigen-specific IgE 
in OVA-immunized mice (54).
Our findings showed that HDI selectively downregulated the 
expression of those genes that are central to CSR and plasma cell 
differentiation processes, that is, Aicda encoding AID cytidine 
deaminase and Prdm1 encoding Blimp-1. They did not, however, 
downregulate the expression of 14-3-3 adaptors, which, as we 
showed, are upregulated by the stimuli that induce CSR and 
are important for AID targeting to S regions in CSR (2, 29, 30, 
32). Rab7, an effective multifunctional regulator of autophagy, 
which activates the canonical NF-κB pathway to induce AID 
expression (35), was also unchanged by HDI. In addition, DNA 
repair factors, such as Ung and TLS DNA polymerases, which 
play important roles for CSR and SHM, were also not altered by 
HDI. Further, epigenetic regulators HATs and HDACs, and Tet 
proteins, genes that are important in cell apoptosis, such as Mcl1, 
Bcl2, and Bcl2l1, TLRs, and genes involved in NF-κB signaling 
also remained unchanged in B cells induced to undergo CSR. 
The selective regulation of gene expression by HDI was consist-
ent with what have been reported in other type of cells (55–58), 
and the level of changes in transcription was associated with 
the type and doses of HDI used and the time of culture (23). 
Although most of the available HDI do not have a high HDAC 
isoform specificity, SCFA HDI have been suggested to display 
significant selectivity for different HDACs. For example, VPA 
targets class I HDACs, particularly, HDAC1 and HDAC2, and, 
less effectively, class IIa HDACs, butyrate targets class I, mainly 
HDAC1, and, less effectively, other members of class I and class 
IIa HDACs. Like HATs, HDACs do not directly bind to DNA, 
rather, they interact with DNA through multi-protein complexes 
that include coactivators and corepressors, the role and composi-
tion of which are often cell type-specific (59). HDAC-associated 
proteins would specify the selectivity of HDI, which display 
different affinities for different HDAC/cofactor complexes. HDI 
with diverse chemical properties target different HDACs and 
HDAC/cofactor complexes, thereby regulating gene expression 
in a locus- and cell type-specific fashion. Thus, the different 
HDAC-associated proteins and the different HDAC/cofactor 
complexes would provide the mechanistic underpinning for the 
selectivity of HDI for specific B cell differentiation genes, as we 
have shown here.
PRDM1/Prdm1 mRNA contains a long (2,453 bp) conserved 
3′ UTR, which comprises putative target sites for multiple miR-
NAs. In addition to miR-23b, miR-30a, and miR-125b, which, 
as we showed by qRT-PCR and miRNA-Seq, are upregulated 
by HDI, several other putative Prdm1 targeting miRNAs, 
including miR-125a, miR-96, miR-351, miR-30c, miR-182, 
miR-23a, miR-200b, miR-200c, miR-365, let-7, miR-98, and 
miR-133, were also significantly increased by HDI. miR-182 
has been identified as the miRNA induced at a high level in B 
cells stimulated to undergo CSR (60); however, deficiency of this 
miRNA did not significantly alter the titers of total serum IgM, 
IgG1, IgG2a, IgG2b, IgG3, IgA, and IgE, and NP-binding IgG1 
in mice immunized with NP-CGG (60). miR-182 is a member of 
the miR-183~182 cluster which includes miR-96, miR-182, and 
miR-183. Like miR-182, miR-96, which, based on its sequence, 
could target all putative miR-182 targeting sites, is also highly 
expressed by B cells induced to undergo CSR and plasma cell 
differentiation (Figure  8), would compensate the function of 
miR-182. miR-183, another member of miR-183~182 cluster, 
was also upregulated by HDI. This together with our finding that 
all members of miR-99b~let-7e~125a cluster were increased by 
HDI further confirm that HDI modulation of miRNA expression 
occurs through modulation of miRNA primary transcript. There 
is no conserved miRNA-targeting site identified in the 3′ UTR 
of Xbp1 mRNA. The 3′ UTR of mouse Xbp1 mRNA contains 
several putative target sites for miR-199, miR-299, miR-433, 
miR-221, and miR-490. None of these miRNAs, however, were 
increased by HDI, supporting the contention that the HDI-
mediated reduction of Xbp1 resulted from decreased Prdm1 
expression (16).
These findings demonstrated that HDI modulate CSR, SHM, 
and plasma cell differentiation, and, therefore, antibody responses 
by downregulating Aicda and Prdm1 expression through upregu-
lation of targeting miRNAs. By significantly extending our recent 
findings (16), it provides further and strong evidence that HDI, 
including those commonly known as “pan-HDI,” can effectively 
modulate a restricted spectrum of miRNAs and, thereby, mRNAs 
in B cells induced to undergo CSR and plasma cell differentia-
tion. This results from HDACs existing in the unique contexts 
of HDAC/cofactor complexes, as occurring in B lymphocytes, 
particularly when in an activated state. The fine specificity of 
the mechanisms of miRNA/mRNA regulation revealed here was 
emphasized by the failure of HDI to modulate a variety of other 
mRNAs encoding elements that participate in but do not initiate 
the processes of events that leads to CSR. Finally, our studies 
also provide mechanistic insights into epigenetic mechanisms 
that directly modulate B cell-intrinsic functions in the immune 
response, thereby offering new clues for further therapeutic 
approaches, as specifically targeted to B cells.
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